By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TWi Pharmaceuticals, Inc. 

4F, No. 41, Lane 221
Kang Chien Rd.
Nei Hu Dist.  Taipei  114 
Phone: 886-2-26573350 Fax: 886-2-26573391


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
TWi Pharmaceuticals, Inc. Receives U.S. FDA Approval On Generic Donepezil Hydrochloride Tablets USP, 23 Mg, Its Fifth ANDA From U.S. FDA 10/30/2014 7:41:56 AM
TWi Pharmaceuticals, Inc. Receives FDA Final Approval On Generic Megestrol Acetate 125mg/Ml Oral Suspension 8/28/2014 11:14:55 AM
TWi Pharmaceuticals, Inc. Announces Settlement Of Lidoderm® Patent Litigation 4/23/2014 8:58:31 AM
TWi Pharmaceuticals, Inc.i Announces ANDA Approval Of Generic Procardia Xl® Tablets 30 Mg, 60 Mg And 90 Mg In The United States 4/7/2014 9:28:15 AM
TWi Pharmaceuticals, Inc. Receives Patent Allowance for Its Reduced Food Effect Metformin Controlled Release Formulation in United States 7/16/2013 10:39:53 AM
TWi Pharmaceuticals, Inc.' Manufacturing Site for the Generic Version of Lidoderm(R) (Lidocane 5% patch) Passes US FDA cGMP Audit and Pre-Approval Inspection 5/29/2013 10:05:00 AM
TWi Pharmaceuticals, Inc. Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets 5/14/2013 9:35:08 AM
Shire plc Settles All Pending Litigation With Anchen Pharmaceuticals(USA), Inc. and TWi Pharmaceuticals, Inc. Concerning INTUNIV® 9/6/2012 11:03:35 AM
TWi Pharmaceuticals, Inc. Announces Positive Phase IIb Clinical Trial Results of AC-201 in Patients With Type 2 Diabetes 8/6/2012 10:44:03 AM
Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes, TWi Pharmaceuticals, Inc. Study 6/14/2011 6:23:26 AM
//-->